Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 11,300 shares, a decline of 19.9% from the February 13th total of 14,100 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 38,300 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. bought a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises about 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th largest holding. Gilead Sciences Inc. owned about 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, January 13th.

Barinthus Biotherapeutics Stock Performance

NASDAQ:BRNS opened at $1.03 on Wednesday. The stock has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.12. Barinthus Biotherapeutics has a one year low of $0.80 and a one year high of $4.16. The company has a market capitalization of $41.43 million, a price-to-earnings ratio of -0.69 and a beta of -0.80.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.